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VEGFThe West Highland white terrier (WHWT) is particularly prone to canine idiopathic pulmonary ﬁbrosis (CIPF).
We hypothesized that higher circulating concentrations of chemokines CXCL8, CCL2, serotonin (5-HT), or vascu-
lar endothelial growth factor (VEGF) could serve as predisposing factors for CIPF development in the WHWT
breed. Serum samples from103healthy dogs of sevendifferent breeds variably predisposed to CIPFwere collected.
Serum CXCL8 concentrations were higher in healthy WHWT compared with each of the other groups of healthy
dogs. Serum CCL2 concentrations were higher in healthy WHWT and Maltese compared with King Charles
spaniels and Malinois Belgian shepherds. No relevant inter-breed differences were observed for serum 5-HT con-
centrations regarding CIPF predisposition. VEGF values from 89.3% of samples testedwere below the kit detection
limit. In conclusion, high CXCL8 blood concentrations and possibly CCL2 concentrations might be related to the
breed predisposition of the WHWT for CIPF and warrants further investigations.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Canine idiopathic pulmonary ﬁbrosis (CIPF) is a progressive paren-
chymal lung disease of unknown origin, which mainly affects older
dogs of the West Highland white terrier (WHWT) breed (Heikkilä-
Laurila and Rajamäki, 2014). Rare cases have also been described in
other terrier breeds such as the Staffordshire terrier (Lobetti et al.,
2001) and the Scottish terrier (Krafft et al., 2011). Pathogenesis of CIPF
is currently unknown, although a genetic basis is strongly suspected
due to the breed predisposition (Heikkilä-Laurila and Rajamäki, 2014).
CIPF shares several clinical features with human IPF (Corcoran et al.,
1999; Lobetti et al., 2001; Heikkilä et al., 2011); however, there are
minor histopathological differences between these entities (Syrjä
et al., 2013). In human IPF, chronic alveolar epithelial cell injuries and
subsequent dysregulated tissue repair are considered to be the main
pathological processes involved in the pathogenesis of this
ﬁbroproliferative disease (Coward et al., 2010; Raghu et al., 2011). The
mechanisms of repair initiated by a tissue injury are complex and areine, Small Animal Department,
3664243.determined by the presence of biological mediators such as growth
factors and chemokines, which coordinate most aspects of the inﬂam-
matory and subsequent repair responses. Consequently, we hypothe-
sized that higher circulating concentrations of pro-ﬁbrotic molecules
in dogs from the WHWT breed may serve as predisposing factors for
CIPF development, by contributing to exacerbated tissue repair after
an injury, leading subsequently to the development of ﬁbrosis. This
hypothesis is further supported by a recent publication focused on
transforming growth factor beta 1 (TGF-β1) demonstrating higher
serum TGF-β1 concentrations in healthy dogs from breeds predisposed
to CIPF in comparisonwith breeds not predisposed to the disease (Krafft
et al., 2014). Therefore, the aim of the present study was to compare
basal circulating blood concentrations of four molecules of interest
obtained in healthy dogs from seven breeds differently predisposed to
CIPF. Selection of molecules studied was based on their potential impli-
cation into the pathogenesis of canine pulmonary ﬁbrosis in view of
data from either human or canine literature and were as follows: the
chemokine (C-X-C motif) ligand 8 (CXCL8) (Cui et al., 2010; Ahn et al.,
2011; Krafft et al., 2013), the chemokine (C-C motif) ligand 2 (CCL2)
(Krafft et al., 2013; Moore, 2014), the serotonin (5-HT) (Konigshoff
et al., 2010; Krafft et al., 2013), and the vascular endothelial growth
factor (VEGF) (Ando et al., 2010; Woodcock et al., 2013).
Table 1







WHWT 18 8/10 9.2 (2.9–16.9) 8.7 (7.4–12.0)
ST 14 3/11 5.1 (0.9–9.5) 10.0 (8.5–13.6)
JRT 16 2/14 7.2 (1.0–11.8) 6.9 (5.9–12.6)
M 15 4/11 6.2 (0.9–12.6) 5.3 (4.0–9.0)
KCS 14 5/9 5.8 (0.5–10.3) 8.3 (6.8–12.0)
LR 12 5/7 5.7 (1.6–12.2) 36.4 (23.0–42.0)
MBS 14 10/4 5.5 (1.5–7.8) 31.2 (23.0–35.0)
WHWT, West Highland white terrier. ST, Scottish terrier. JRT, Jack Russell terrier.
M, Maltese. KCS, King Charles spaniel. LR, Labrador retriever. MBS, Malinois Belgian
Shepherd.
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2.1. Source of samples and ethics statement
A total of 103 healthy dogs from sevendifferent breedswere included
in this study. Ninety-three of these dogs were examined and sampled at
the University of Liege, Belgium, and the remaining 10 at the University
of Helsinki, Finland. Breeds selected were WHWT, Scottish terrier (ST),
Jack Russell terrier (JRT), Maltese (M), King Charles spaniel (KCS),
Labrador retriever (LR), and Malinois Belgian Shepherd (MBS). Those
breeds were considered as highly (WHWT), possibly (ST, JRT), or not
(M, KCS, LR, MBS) –CIPF predisposed breeds. ST and JRT were chosen
as terrier breeds potentially predisposed to CIPF; given that one CIPF
case has already been conﬁrmed by histopathology in a dog from the
ST breed (Krafft et al., 2011) and that CIPF has been clinically suspected
in ﬁve JRT, but not histopathologically conﬁrmed (personal observa-
tions). M breed was chosen as a non-terrier breed sharing similarities
in weight and size with theWHWT breed. KCS breedwas chosen as an-
other small-size non-terrier breed predisposed for degenerative mitral
valve disease (DMVD), another ﬁbrotic disease (Borgarelli and
Buchanan, 2012). LR andMBS breedswere chosen as large breeds deﬁn-
itively not predisposed to ﬁbrotic lung disease. All dogs included were
privately owned, and sampleswere obtained after acquiring thewritten
consent of the owners. The study protocol was approved by the
Committee of Experimental Animals of the University of Liège,
Belgium (permit number: 1435, date of approval: 14 March 2013) and
by the equivalent committee of Western Finland (permit number:
ESLH-2008-05403, date of approval: 27 June 2008; ESAVI/7383/
04.10.07/2013, date of approval: 13 November 2013). Detailed features
of the study population are summarized in Table 1. Health status was
based on complete history and physical examination in all dogs, in ad-
dition to routine hematologic and serum biochemical examinations in
87% and 79% of dogs, respectively. A thoracic high-resolution computed
tomography (HRCT) was performed in nine out of 18 clinically healthy
WHWT and did not reveal any abnormalities. Besides, all included
WHWTwere followedup at various time intervals after blood sampling.
Thirteen of themwere still alive at the time of writing, 1.1–6 years after
sampling of the blood used in the present study. So far, none of them
have developed any respiratory complaint as determined by telephone
consultationwith the owners. The remainingﬁve dogswere euthanized
or died within 6 months to 4.6 years after blood sampling, for reasons
unrelated to the respiratory system; lung tissue samples were available
in three of these dogs (2.6, 4.4, and 4.6 years after blood sampling,
respectively). On lung histopathology, mild interstitial ﬁbrosis was
noticed in all three dogs, but none of them ever displayed any signs
compatible with CIPF. Given the time interval between blood sampling
and lung histopathology and the absence of clinical signs, blood samples
from those three dogs were not discarded.
2.2. Samples processing
Blood samples were obtained in plain tubes from all dogs. Thirtymi-
nutes after blood collection, tubes were centrifuged at 4 °C for 15min at
1300 × g. Serum was harvested and transferred into 1.5 mL plastic
cryotubes, and samples were stored at −80 °C until analysis. Serum
CXCL8, CCL2, and VEGF measurements were performed using commer-
cial canine ELISA kits (R&D Systems) in duplicate, according to the
manufacturer's instructions. Serum 5-HT measurement was performed
using a commercial human ELISA kit (IBL international) previously
validated in dogs (Ljungvall et al., 2013).
2.3. Statistical methods
Descriptive statistics (XLStat software, Addinsoft) was used for
clinical (gender, age, and weight), biochemical, and hematologic re-
sults; data were reported as median and range. Serum CXCL8, CCL2,and 5-HT concentrationswere compared between breeds using a global
linear model (SAS software, SAS Institute Inc.) integrating the effects of
age and gender as covariables; data were expressed as least square
mean ± SE. Proportions were compared using the Chi2 test with the
threshold 5%, data were expressed as percentage (XLStat software,
Addinsoft). P-values ≤ 0.05 were considered as signiﬁcant.
3. Results and discussion
3.1. Physical, biochemical, and hematologic examination
Physical examination was unremarkable in all dogs included in this
study. Dogs did not have any signs or ﬁndings indicating disease.
Biochemical and hematologic data are summarized in Table 2. Most
measured parameters were within laboratory reference ranges or only
discreetly increased, except for alkaline phosphatase (ALP) and platelet
count. ALP was above the upper limit of reference range in most dogs
from WHWT (73%) and ST (75%) breeds; these percentages were high
in comparison with those obtained in M (8%), KCS (7%), LR (13%), and
MBS (0%) (P b 0.0001). These observations are in agreementwith previ-
ously published data indicating an increased ALP activity in dogs from
the WHWT and ST breeds (Gallagher et al., 2006; Nestor et al., 2006;
Heikkilä et al., 2011), and possibly attributed in ST to benign subclinical
hyperadrenocorticism (Zimmerman et al., 2010). Whether such phe-
nomenon also exists in the WHWT breed has not been investigated.
Platelet count was below the lower limit of reference range in most
dogs from KCS (54%) breed compared with other breeds: WHWT
(0%), ST (7%), JRT (0%), M (0%), LR (29%), and MBS (23%) (P = 0.002
vs. WHWT, JRT, and M). In thrombocytopenic KCS, macrothrombocytes
were observed on blood smear. This ﬁnding can be related to the exis-
tence of an autosomal mutation in beta1-tubulin gene in KCS leading
to asymptomatic macrothrombocytopenia in this breed (Davis et al.,
2008). On the opposite, platelet count was most frequently above the
upper limit of reference range in WHWT dogs (39%) compared with
other breeds: ST (21%), JRT (17%), M (8%), KCS (15%), LR (0%), and
MBS (8%) (P= 0.147). Thrombocytosis in apparently healthy WHWT,
although not signiﬁcant in the present study, has already been reported
previously (Heikkilä et al., 2011). In human IPF patients, increased
platelet reactivity has recently been demonstrated and may participate
to the ﬁbroproliferative process observed in the disease by the release of
pro-ﬁbroticmediators such as TGF-β1 (Fernandez andEickelberg, 2012;
Crooks et al., 2014). In dogs, although the reactivity of platelets has not
been investigated, a similar hypothesis might explain why breeds with
high basal platelet numbers would be more prone to develop lung
ﬁbrosis.
3.2. CXCL8 and CCL2 concentrations
Serum CXCL8 and CCL2 concentrations (pg/mL) are presented in
Figs. 1 and 2, respectively. Signiﬁcantly higher serum CXCL8 concentra-
tions were observed in healthy WHWT in comparison with all other
groups of healthy dogs (P ≤ 0.05). Signiﬁcant differences were also
Table 2
Biochemical and hematologic data.
Breed WHWT ST JRT M KCS LR MBS References
TP, 62 67 59 61 65 67 68 60–80
(g/L) (52–74) (54–87) (50–73) (52–70) (60–75) (65–72) (56–71)
Creat, 79.3 81.7 89.3 90.2 73.1 112.5 80.4 b133
(μmol/L) (65.0–115.7) (60.8–93.0) (74.1–106.4) (78.9–101.9) (55.7–97.5) (57.2–144.4) (51.3–122.3)
ALT, 37 47 71 34 33 58 50 5–62
(IU/L) (23–156) (26–158) (47–133) (23–156) (19–288) (39–119) (23–73)
ALP, 191 176 64 40 63 56 54 12–121
(IU/L) (40–654) (32–816) (24–235) (9–136) (29–125) (23–269) (21–117)
Ht, 51 58 50 48 42 49 52 37–55
(%) (38–59) (46–67) (43–59) (42–54) (34–47) (35–56) (46–58)
WBC, 7820 7925 9160 7340 9040 8070 9000 6000–15000
(× 106 μ/L) (4130–11800) (4590–22200) (6830–11900) (4770–14600) (6020–15160) (4480–18100) (5970–13400)
Plt, 446 383 414 437 180 225 247 200–500
(× 103 μ/L) (254–754) (136–543) (248–554) (248–535) (54–625) (72.5–340) (92–560)
WHWT, West Highland white terrier. ST, Scottish terrier. JRT, Jack Russell terrier. M, Maltese. KCS, King Charles spaniel. LR, Labrador retriever. MBS, Malinois Belgian Shepherd. TP, total
protein. Creat, creatinine. ALT, alanine-amino transferase. ALP, alkaline phosphatase.Ht, hematocrit.WBC,white blood cell count. Plt, platelet count. Data areexpressed asmedian and range.
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centrations were signiﬁcantly higher in healthy WHWT and M in com-
parison with KCS and MBS (P ≤ 0.05). A signiﬁcant difference for
serum CCL2 concentrations was also observed between LR and MBS
(P=0.04). Effects of age and gender on serumCCL2 and CXCL8 concen-
trations were not signiﬁcant.
In humans, both CXCL8 and CCL2 concentrations were found to be
increased in blood (Ziegenhagen et al., 1998a; Suga et al., 1999;
Fujiwara et al., 2012) and bronchoalveolar lavage ﬂuid (BALF) (Capelli
et al., 2005; Antoniou et al., 2006; Baran et al., 2007) of IPF patients com-
pared with healthy volunteers and correlated with lung function
(Capelli et al., 2005; Emad and Emad, 2007; Martina et al., 2009;Fig. 1. Box plot of serum CXCL8 concentrations (pg/mL) obtained from healthy West
Highland white terriers (WHWT, n = 18), Scottish terriers (ST, n = 14), Jack Russell
terriers (JRT, n= 16), Maltese (M, n= 15), King Charles spaniels (KCS, n= 14), Labrador
retrievers (LR, n = 12), and Malinois Belgian Shepherds (MBS, n = 14). The box repre-
sents the interquartile range, with the median indicated by the horizontal line. The whis-
kers extend from the minimum to the maximum values, excluding outliers that are
presented by an open circle or extreme outliers that are presented by asterisks.
†Statistically different fromWHWT (P ≤ 0.05). ‡Statistically different from M (P ≤ 0.008).Vasakova et al., 2009), disease progression (Ziegenhagen et al., 1998b;
Totani et al., 2002), and outcome (Shinoda et al, 2009; Richards et al.,
2012). Furthermore, several studies suggested an involvement of the
chemokine CCL2 in the pathogenesis of IPF, notably through its action
on resident pulmonary ﬁbroblast and circulating ﬁbrocytes, promoting
the generation of abundant extracellular matrix in the lungs
(Gharaee-Kermani et al., 1996; Phillips et al., 2004; Moore et al., 2005;
Inomata et al., 2014). Such strong evidence involving CXCL8 in the path-
ogenesis of the disease are lacking, although this chemokine is thought
to act as a pro-ﬁbrotic factor in IPF via the promotion of exacerbatedFig. 2. Box plot of serum CCL2 concentrations (pg/mL) obtained from healthy West
Highland white terriers (WHWT, n = 18), Scottish terriers (ST, n = 14), Jack Russell
terriers (JRT, n= 16), Maltese (M, n= 15), King Charles spaniels (KCS, n= 14), Labrador
retrievers (LR, n = 12), and Malinois Belgian Shepherds (MBS, n = 14). The box repre-
sents the interquartile range, with the median indicated by the horizontal line. The whis-
kers extend from the minimum to the maximum values, excluding outliers that are
presented by an open circle or extreme outliers that are presented by asterisks.
†Statistically different from WHWT and M (P ≤ 0.01). ‡Statistically different from L
(P= 0.04).
Fig. 3. Box plot of serum 5-HT concentrations (ng/mL) obtained from healthy West
Highland white terriers (WHWT, n = 18), Scottish terriers (ST, n = 14), Jack Russell
terriers (JRT, n= 16), Maltese (M, n= 15), King Charles spaniels (KCS, n= 14), Labrador
retrievers (LR, n = 12), and Malinois Belgian Shepherds (MBS, n = 14). The box repre-
sents the interquartile range, with the median indicated by the horizontal line. The whis-
kers extend from the minimum to the maximum values, excluding outliers that are
presented by an open circle or extreme outliers that are presented by asterisks.
†Statistically different from ST, M, KCS, and MBS (P ≤ 0.05).
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Antoniou et al., 2006; Martina et al., 2009; Cui et al., 2010).
In dogs, mRNA expression of CXCL8 and CCL2 was found to be
increased in CIPF lungs compared with controls (Krafft et al., 2013).
Higher CXCL8 concentrations were found in BALF, but not in serum, of
WHWT with CIPF in comparison with healthy WHWT, and both BALF
and serum CCL2 concentrations were shown to be increased in
WHWT with CIPF compared with healthy WHWT (Krafft et al., 2013;
personal communications).
In the present study, ﬁnding various serumCXCL8 and CCL2 concen-
trations in healthy dogs from different breeds suggests that such con-
centrations might be genetically determined in dogs. Although not
proven, a cause–effect relationship between the development of CIPF
and the high circulating CXCL8 and CCL2 concentrations observed in
healthyWHWTmight exist. A similar hypothesis was already proposed
for serumTGF-β1 concentrationswhichwere also found to be increased
in healthy WHWT compared with breeds less predisposed to CIPF
(Krafft et al., 2014). However, not all dogs from theWHWTbreed devel-
op the disease at an advanced age. Therefore, the high serum TGF-β1,
CXCL8, or even CCL2 concentrations found in apparently healthy
WHWT might serve as one of the multiple predisposing factors for
CIPF development by triggering an inappropriate lung response after
an injury, leading subsequently to pulmonary ﬁbrosis. In humans,
whether healthy people with increased CXCL8, CCL2, or TGF-β1 blood
concentrations are speciﬁcally at risk for development of ﬁbrosis has
not been studied. Nevertheless, some studies highlighted the fact that
IPF patients with a high TGF-β1 producing genotype are incline to
have a worse prognosis and a more rapid deterioration in lung function
(Arkwright et al., 2000; Alhamad et al., 2013). A single nucleotide poly-
morphism (rs4073T N A) was also recently found in the promoter of the
CXCL8 gene and was signiﬁcantly associated with higher BALF CXCL8
concentrations and an increased risk of development of IPF in humans
(Ahn et al., 2011). Existence of such polymorphism in CIPF dogs has
not yet been investigated.
Increased serum CCL2 concentrations observed in healthy M in the
present study does not seem to predispose this breed to a ﬁbrotic dis-
ease. In human medicine, the chemokine CCL2, while involved in the
pathogenesis of IPF, is also involved in a variety of other diseases, rang-
ing from immune-mediated and vascular diseases to cancer (Locati et al,
2005). Whether the high serum CCL2 concentrations observed in
healthy M might predispose this breed to speciﬁc pathological condi-
tions is unknown.3.3. Serum 5-HT concentrations
Serum 5-HT concentrations (ng/mL) obtained in healthy KCS, ST, M,
andMBSwere signiﬁcantly higher in comparisonwith those obtained in
healthy WHWT, JRT, and LR (P ≤ 0.05). Data are presented in Fig. 3.
Effects of age and gender were not signiﬁcant. These results do not indi-
cate relevant interbreed differences regarding CIPF predisposition and
are not in favor of any inﬂuence of basal 5-HT concentrations on CIPF
development in WHWT. In humans, altered regulation of the serotonin
pathway is thought to be associated with the development of pulmo-
nary ﬁbrosis since an increased expression of 5-HT receptors was
found in IPF lungs (Fabre and Crestani, 2010; Konigshoff et al., 2010)
and anti-serotonin therapywas shown to attenuate induced pulmonary
ﬁbrosis in mice (Konigshoff et al., 2010; Skurikhin et al., 2012). In dogs,
5-HT has essentially been studied in the pathogenesis of the DMVD, an-
other ﬁbrotic disease (Oyama and Levy, 2010; Ljungvall et al., 2013;
Cremer et al., 2014; Mangklabruks and Surachetpong, 2014). Increased
5-HT blood concentrations were found in healthy KCS in comparison
with healthy dogs from other breeds predisposed or not to DMVD
(Arndt et al., 2009). In the present study, although KCS displayed the
highest serum 5-HT concentration, the difference with other breeds
was only signiﬁcant in comparison with WHWT, JRT, and LR.3.4. Serum VEGF concentrations
The majority of samples tested for serum VEGF concentrations, 92
out of 103 (89.3%), were below the ELISA kit detection limit
(39.1 pg/mL). By consequence, a quantitative comparison between
breeds was not possible. Results above the kit detection limit were
found in 3 KCS (21.4%), 3 JRT (18.8%), 3 LR (25.0%), 1 WHWT (5.6%),
and 1 ST (7.1%). Frequency of positive results was not different between
breed groups (P=0.147). In humans, VEGF was found signiﬁcantly de-
creased in BALF of IPF patients compared with healthy volunteers
(Koyama et al., 2002) and serumconcentrationswere found to correlate
with the disease progression (Ando et al., 2010). Moreover, nintedanib,
a tyrosine kinase receptor antagonist which inhibits a number of key
receptors including the VEGF receptor, was proven to slow down the
progression of the disease and to improve the quality of life in patients
with IPF (Woodcock et al., 2013). These observations made in human
IPF enhance the interest toward the VEGF molecule in CIPF, although
results of the present study were not conclusive due to the assay
limitation.3.5. Limitations
Limitations of the present study were that only half of the healthy
WHWT underwent a thoracic HRCT and that thoracic X-rays were not
available for the healthy other dogs included in this study. Moreover,
although CIPF HRCT ﬁndings were described in detail (Johnson et al.,
2005; Heikkilä et al., 2011), the sensitivity of this imaging technique
for detection of early lung lesions has not been established. Therefore,
some included WHWT, even the ones that underwent a thoracic
HRCT, might already have subclinical CIPF lesions at the time of
61E. Roels et al. / Research in Veterinary Science 101 (2015) 57–62sampling, which could have interfered with the results of the present
study. This is unlikely, in view of absence of development of respiratory
clinical signs in time intervals ranging from 6 months to 6 years after
blood sampling. However, the mild interstitial ﬁbrosis noticed on lung
histopathology from three included WHWT (2.6–4.6 years after blood
sampling), without evidence of CIPF clinical signs, highlights the poten-
tial existence of a subclinical CIPF state in dogs from the WHWT breed.
Another limitation of the present study could be that some dogs includ-
ed, no matter from which breed they are belonging, may have suffered
from subclinical inﬂammatory or neoplastic diseases at the time of
sampling, that could have inﬂuenced serum concentrations.4. Conclusion
The present study demonstrated increased serum CXCL8 concentra-
tions in healthy dogs from the WHWT breed in comparison with other
breeds less or not predisposed to CIPF. Serum CCL2 concentrations
were increased in healthy WHWT, but also in M, a non CIPF-
predisposed breed. No relevant interbreed differences were observed
for 5-HT with regard to CIPF predisposition. Breed-related differences
in VEGF blood concentrations could not be investigated since most of
the results obtained were below the kit detection limit. Increased
serum CXCL8 concentrations, and possibly CCL2 concentrations, found
in healthy WHWT might be related to the breed predisposition of the
WHWT for CIPF and possibly serve as predisposing factor for disease de-
velopment. Further investigations are warranted to explore how those
chemokines systemically and locally participate to pulmonary ﬁbrosis
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